Cargando…
Novel Treatments Paradigms: Membranous Nephropathy
Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused by antiphospholipase A2 receptor (PLA2R) antibodies, although several new target antigens have been recently identified. It is chara...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014375/ https://www.ncbi.nlm.nih.gov/pubmed/36938069 http://dx.doi.org/10.1016/j.ekir.2022.12.011 |
_version_ | 1784906981181489152 |
---|---|
author | Rojas-Rivera, Jorge E. Ortiz, Alberto Fervenza, Fernando C. |
author_facet | Rojas-Rivera, Jorge E. Ortiz, Alberto Fervenza, Fernando C. |
author_sort | Rojas-Rivera, Jorge E. |
collection | PubMed |
description | Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused by antiphospholipase A2 receptor (PLA2R) antibodies, although several new target antigens have been recently identified. It is characterized by the diffuse thickening of the glomerular basement membrane secondary to immune complex deposition. In patients with persistent NS without response to maximizing conservative therapy including the use of renin-angiotensin system (RAS) blockers, the use of immunosuppressive agents is warranted. However, the optimal immunosuppressive treatment has not yet been established. Classical immunosuppressants, such as cyclophosphamide plus steroids, are effective but may cause clinically relevant adverse effects, limiting their use. Rituximab offers efficacy with a better safety profile whereas calcineurin inhibitors (CNIs) are marred by high relapse rates and nephrotoxicity. Nevertheless, up to 30% of patients fail to respond to standard therapy. Novel and specific therapies targeting B cells and plasma cells have shown encouraging preliminary results, in terms of clinical efficacy and safety profile, especially in patients with poor tolerance or refractory to conventional treatments. In this brief review, we discuss the benefits and limitations of the current therapeutic approach to MN and describe emerging novel therapies that target its pathogenesis. |
format | Online Article Text |
id | pubmed-10014375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100143752023-03-16 Novel Treatments Paradigms: Membranous Nephropathy Rojas-Rivera, Jorge E. Ortiz, Alberto Fervenza, Fernando C. Kidney Int Rep Review Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused by antiphospholipase A2 receptor (PLA2R) antibodies, although several new target antigens have been recently identified. It is characterized by the diffuse thickening of the glomerular basement membrane secondary to immune complex deposition. In patients with persistent NS without response to maximizing conservative therapy including the use of renin-angiotensin system (RAS) blockers, the use of immunosuppressive agents is warranted. However, the optimal immunosuppressive treatment has not yet been established. Classical immunosuppressants, such as cyclophosphamide plus steroids, are effective but may cause clinically relevant adverse effects, limiting their use. Rituximab offers efficacy with a better safety profile whereas calcineurin inhibitors (CNIs) are marred by high relapse rates and nephrotoxicity. Nevertheless, up to 30% of patients fail to respond to standard therapy. Novel and specific therapies targeting B cells and plasma cells have shown encouraging preliminary results, in terms of clinical efficacy and safety profile, especially in patients with poor tolerance or refractory to conventional treatments. In this brief review, we discuss the benefits and limitations of the current therapeutic approach to MN and describe emerging novel therapies that target its pathogenesis. Elsevier 2023-01-02 /pmc/articles/PMC10014375/ /pubmed/36938069 http://dx.doi.org/10.1016/j.ekir.2022.12.011 Text en © 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Rojas-Rivera, Jorge E. Ortiz, Alberto Fervenza, Fernando C. Novel Treatments Paradigms: Membranous Nephropathy |
title | Novel Treatments Paradigms: Membranous Nephropathy |
title_full | Novel Treatments Paradigms: Membranous Nephropathy |
title_fullStr | Novel Treatments Paradigms: Membranous Nephropathy |
title_full_unstemmed | Novel Treatments Paradigms: Membranous Nephropathy |
title_short | Novel Treatments Paradigms: Membranous Nephropathy |
title_sort | novel treatments paradigms: membranous nephropathy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014375/ https://www.ncbi.nlm.nih.gov/pubmed/36938069 http://dx.doi.org/10.1016/j.ekir.2022.12.011 |
work_keys_str_mv | AT rojasriverajorgee noveltreatmentsparadigmsmembranousnephropathy AT ortizalberto noveltreatmentsparadigmsmembranousnephropathy AT fervenzafernandoc noveltreatmentsparadigmsmembranousnephropathy |